Mark S. Ordan
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Carlyle Schedules Q3 Earnings as Shares Fall and Targets Cut. Carlyle Secured Lending has scheduled its Q3 earnings release and conference call for the quarter ended September 30, 2026. In recent trading, the company's shares fell, as reported in a market roundup. Analysts at UBS and TD Cowen lowered their price targets to $60 and $42, citing concerns such as the risk of private‑credit exposure to a growing AI financing wave that Carlyle highlighted.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
FRT Acquires The Summit For $508M Amid Analyst Downgrades. Federal Realty Investment Trust acquired The Summit in Alabama for $508 million, expanding its retail portfolio. This move coincides with Truist Securities lowering its price target to $116 and Barclays cutting its target to $118, both maintaining neutral stances. The stock is currently trading near key support levels, reflecting a cautious market outlook for the REIT sector.
Transaction History
| MD | ▼ Sell | Other | 97,174 | $0 | 6/2/2026 | View on chart |
| MD | ▲ Buy | Grant | 97,174 | $0 | 6/2/2026 | View on chart |
| MD | ▲ Buy | Grant | 127,198 | $0 | 6/1/2026 | View on chart |
| MD | ▼ Sell | Tax Withholding | 19,119 | $412K | 6/1/2026 | View on chart |
| CG | ▲ Buy | Grant | 4,450 | $0 | 5/1/2026 | View on chart |
| CG | ▲ Buy | Grant | 4,450 | $220K | 5/1/2026 | View on chart |
| MD | ▼ Sell | Open Market | 23,000 | $515K | 12/15/2025 | View on chart |
| MD | ▲ Buy | Grant | 194,347 | $0 | 6/1/2025 | View on chart |
| MD | ▼ Sell | Tax Withholding | 7,225 | $104K | 5/9/2025 | View on chart |
| CG | ▲ Buy | Grant | 5,235 | $0 | 5/1/2025 | View on chart |
| MD | ▼ Sell | Open Market | 27,600 | $424K | 11/13/2024 | View on chart |
| MD | ▲ Buy | Grant | 18,360 | $0 | 5/9/2024 | View on chart |
| CG | ▲ Buy | Grant | 5,004 | $0 | 5/1/2024 | View on chart |
| MD | ▼ Sell | Open Market | 33,000 | $438K | 5/25/2023 | View on chart |
| MD | ▲ Buy | Grant | 9,463 | $0 | 5/11/2023 | View on chart |
| CG | ▲ Buy | Grant | 6,238 | $0 | 5/1/2023 | View on chart |
| MD | ▼ Sell | Tax Withholding | 98,932 | $1.5M | 12/31/2022 | View on chart |
| MD | ▼ Sell | Open Market | 22,166 | $342K | 11/21/2022 | View on chart |
| CG | ▲ Buy | Grant | 5,236 | $0 | 5/1/2022 | View on chart |
| MD | ▲ Buy | Grant | 76,253 | $0 | 3/1/2022 | View on chart |
| MD | ▲ Buy | Grant | 76,253 | $0 | 3/1/2022 | View on chart |
| MD | ▼ Sell | Tax Withholding | 20,691 | $486K | 3/1/2022 | View on chart |
| FRT | ▲ Buy | Grant | 880 | $0 | 1/3/2022 | View on chart |
| MD | ▲ Buy | Option Exercise | 95,000 | $1.7M | 8/30/2021 | View on chart |
| MD | ▼ Sell | Open Market | 95,000 | $3.3M | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
MD mentioned in list of stocks with questionable fundamentals
Pediatrix Medical Group (MD) was recently included in a Yahoo Finance article highlighting three unpopular stocks with questionable fundamentals. This mention draws attention to the company's valuation and financial metrics, placing it in a category that some market observers view with caution. The stock currently trades near its 52-week high range, with an average analyst target price of $26.33.
MD mentioned in list of stocks with questionable fundamentals. Pediatrix Medical Group (MD) was recently included in a Yahoo Finance article highlighting three unpopular stocks with questionable fundamentals. This mention draws attention to the company's valuation and financial metrics, placing it in a category that some market observers view with caution. The stock currently trades near its 52-week high range, with an average analyst target price of $26.33.